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Introduction
Tryptophan (TRY) is an amino acid participating in  biosynthesis 
of proteins and methoxyindoles (serotonin and melatonin) 
(reviewed in ref. 1). TRY 2,3-dioxygenase 2 (TDO) is a rate-lim-
iting enzyme of the major non-protein route of TRY metabolism: 
the cleavage of indole ring of TRY with the formation of formyl-
kynurenine, and subsequently, kynurenine (KYN).2 Since TDO 
is intracellular enzyme,3 TRY must enter cell to be available as a 
substrate for KYN formation. Cellular uptake of TRY is facili-
tated by ATP-binding cassette (ABC) transporter.4 Thus, besides 
TDO, ABC transporter is a rate-limiting factor of TRY conver-
sion into KYN.5
Animal and human studies suggested that aging is associated 
with upregulation of TRY-KYN metabolism. Thus, plasma KYN/
TRY ratio (marker of activity of KYN formation from TRY) is 
increased with aging.6,7 Increased formation of KYN derivative, 
kynurenic acid, was observed in aged rat brain8,9 and in human 
serum.10 One of the mechanisms of aging-associated upregulation 
of TRY-KYN metabolism might be the increased production of 
cortisol,11 the inducer of TDO. Association between TRY-KYN 
metabolism and aging might be further supported by the obser-
vations of the increased rate of TRY conversion into KYN in 
obesity, diabetes, atherosclerosis, menopause, major depression 
and other aging-associated medical and  psychiatric disorders 
 (including metabolic syndrome).12,13
upregulation of kynurenine (KYN) formation from tryptophan (trY) was associated with aging in animal and human 
studies. trY-KYN metabolism is affected by the activities of trY 2,3-dioxygenase 2 (tDO) and atP-binding cassette (aBC) 
transporter regulating trY access to intracellular tDO. We studied the effects of tDO inhibitor, alpha-methyl tryptophan 
(amt) and aBC transported inhibitor, 5-methyl tryptophan (5mt), on the life span of wild strain female Drosophila flies 
(Oregon-r). amt and 5mt prolonged mean and maximum life span (by 27% and 43%, and 21% and 23%, resp.). the 
present results are the first observation of the extension of life span of Drosophila melanogaster by inhibitors of trY-
KYN metabolism, and in line with literature and previous studies on prolonged life span of tDO- and aBC-deficient 
female Drosophila mutants. inhibition of tDO and aBC transporter activity might offer the new target for anti-aging 
interventions.
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TRY-KYN pathway and related genes were described in 
Drosophila melanogaster.14 The end product of TRY-KYN path-
way in Drosophila is brown eye pigment.15 TDO is the rate-limit-
ing enzyme of KYN formation from TRY in Drosophila, as in the 
other species. Life spans of TDO-deficient (vermilion) 16,17 and of 
ABC transport impaired (white) eye mutants of Drosophila mela-
nogaster were longer than of wild type flies.17 This data are in line 
with the observation of high mortality in humans with increased 
plasma KYN/TRY ratio at the entry of the 10-year prospective 
study of nonagenarians.18 Therefore, we suggested that prolonga-
tion of life span might be associated with the slow rate of KYN 
formation from TRY.13,17
To further evaluate this hypothesis we were interested to study 
the effect of TDO inhibitor, alpha-methyl tryptophan (aMT) 19 
and of ABC transporter inhibitor, 5-methyltryptophan (5MT),5 
on the life span of wild type Oregon flies.
Results
Effect of alpha-methyl tryptophan. Treatment with aMT 
(0.46 mM) did not affect the life span of Drosophila (data not 
shown).
Treatment with higher concentration of aMT (18.3 mM) 
increased mean survival time (by 27%, p < 0.0001) and 
maximum life span (by 23%, p < 0.0001, two way ANOVA) 
(Table 1).
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previous observations of prolonged life span of TDO-deficient 
eye color mutants (vermilion) of Drosophila.16,17
Aging might be affected by the manipulations of the up-
stream biochemical pathways of TRY metabolism. Thus, reduc-
ing the TRY content of the diet extended maximum life span in 
mammals.20 Since TRY is required for the synthesis of proteins 
and methoxyindoles (serotonin, N-acetylserotonin and melato-
nin),1 dietary reductions of TRY might not be advisable. It is 
noteworthy that TRY participation in protein biosynthesis is not 
affected by inhibition of ABC transporter.5
TRY has to enter the cell to interact with intracellular TDO.3 
TRY shares the same ABC transporter with guanine, the initial 
substrate for formation of the red eye pigment of Drosophila.21 
Since the eye color of wild stock Drosophila depends on a com-
bination of red and brown pigments, mutants with impaired 
ABC transporter of both guanine and TRY have no eye pig-
ment, and hence, have white colored eyes.22 Prolonged life span 
was observed in white mutants of Drosophila.17 ABC trans-
porter is encoded by white gene, and inhibition of ABC trans-
porter by 5MT was observed in in vitro experiments.5 Since 
TRY is transported by ABC transporter, administration of 
5MT might prolong life span by inhibiting TRY-KYN metabo-
lism. However, ABC transporter might be involved in transport 
of KYN,5 3-hydroxy KYN,4 and cGMP.23 Further studies with 
the assessment of the effect of 5MT on the content of TRY, 
KYN, and its metabolites are needed to explain the effect of 
5MT on life span.
In conclusion, prolongation of life span was observed in 
wild stock flies treated by the inhibitors of TDO and of ABC 
transporter. Both treatments supposed to limit TRY conversion 
into KYN. This data are in agreement with previously observed 
extension of life span in Drosophila mutants with deficient 
TDO16,17 or impaired ABC transporter,17 and with neuroprotec-
tive effect of genetic inhibition of TDO.24 Importantly, in dif-
ference with genetic mutations, pharmacological interventions 
increased not only mean survival time but maximum life span as 
well. Inhibition of TRY conversion into KYN might be a target 
for anti-aging intervention.
Future studies might explore the effect of potential inhibitors 
of TDO and ABC transporter among tryptophan derivatives25,26 
on the life span of Drosophila and other species.
Methods
Female wild-type stock Oregon of Drosophila melanogaster from 
the collection of V.N. Karazin Kharkiv National University was 
used in the experiments and maintained at 23°C on a standard 
Drosophila medium consisting of sugar, yeast, agar and semo-
lina. Two concentrations of aMT (alpha-DL-methyl tryptophan) 
(0.46 mM or 18.3 mM) or 5MT (5-methyl-DL-tryptophan) (2.4 
mM and 34.5 mM) (Sigma Aldrich Chemical Co., USA) were 
added to nutrition medium of experimental groups. To examine 
life span, 1-day-old adult flies were collected and then regularly 
transferred to fresh medium every 3–4 days. The number of dead 
flies was recorded at the time of transfer. The study was carried 
out between April and June.
Maximum life span of female control group was 53 days. 25% 
(13 out of 51) flies treated with high concentrations of aMT sur-
vived longer than 53 days (up to 65 days) (Fig. 1).
Effect of 5-methyl tryptophan. Treatment with 5MT (2.4 
mM) did not affect the life span of Drosophila (data not shown).
Treatment with higher concentration of 5MT (34.5 mM) 
increased mean survival time (by 21%) and maximum life span 
(by 23%) of flies (p < 0.0001, two way ANOVA) (Table 1).
Maximum life span of female control group was 53 days. 19% 
(11 out of 58) female flies treated with high concentrations of 
5MT survived longer than 53 days (up to 65 days) (Fig. 1).
Discussion
This is the first (as far as we know) observation of the prolon-
gation of life span in Drosophila by TDO inhibitor, aMT, and 
by ABC transporter inhibitor, 5MT. The effect appeared to be 
a dose-dependent: prolongation of life spam was observed only 
with high but not low concentrations of aMT and 5MT. Intra-
thorasic administration of aMT inhibited TDO in domestic 
flies,19 and TRY-KYN metabolism is similar in domestic flies and 
Drosophila melanogaster: in both species the end product of TRY-
KYN pathway is brown eye pigment, ommochrome. Therefore, 
aMT effect on life span is, most likely, related to inhibition of 
TDO. However, the direct assessment of TDO activity is needed 
to proof this suggestion. The present results are in line with the 
Table 1. inhibitors of tryptophan—kynurenine metabolism and life 
span of female Drosophila melanogaster (Oregon)
Control (days)  
(n = 50)
aMT (days)  
(n = 51)
5MT (days)  
(n = 58)
mean 40.1 51.7* 48.5*
Std. err. 1.4 0.9 1.0
maximum 53 65* 46*
Concentrations of amt (18.3 mm) and 5mt (34.5 mm); *increase in days 
in comparison with control group; p < 0.0001, two-way aNOVa.
Figure 1. Survival time of Drosophila melanogaster (Oregon) treated 
with alpha-methyl (amt) and 5-methyl (5mt) tryptophan (p < 0.0001, 
Logrank test).
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